Samsung Biologics: geographic diversification is a sound business decision
In a Pharmaceutical Technology article, Samsung Biologics details its geographic diversification strategy. The CDMO acquired GSK's Rockville, Maryland facility in March 2026, marking its first US manufacturing presence and raising global capacity to 845,000 L. A subsequent agreement to acquire Switzerland's PolyPeptide Group adds peptide therapeutics capabilities and sites across Sweden, Belgium, France, the US, and India.
James Choi, EVP and Head of Sales Support, states the expansion was planned over several years, driven by client demand for supply chain diversification and risk mitigation rather than US onshoring pressure. "Geographic diversification has proven to be a sound business decision," he says.
In a Pharmaceutical Technology article, Samsung Biologics details its geographic diversification strategy. The CDMO acquired GSK's Rockville, Maryland facility in March 2026, marking its first US manufacturing presence and raising global capacity to 845,000 L. A subsequent agreement to acquire Switzerland's PolyPeptide Group adds peptide therapeutics capabilities and sites across Sweden, Belgium, France, the US, and India.
James Choi, EVP and Head of Sales Support, states the expansion was planned over several years, driven by client demand for supply chain diversification and risk mitigation rather than US onshoring pressure. "Geographic diversification has proven to be a sound business decision," he says.
Share article
Related Content